Human Dopaminergic Progenitor Cells Clinical Trials
4 recruitingBiologic
Phase 14Phase 21
Showing 1–4 of 4 trials
Recruiting
Phase 1
A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy
Multiple System Atrophy - Parkinsonian Subtype (MSA-P)
iRegene Therapeutics Co., Ltd.9 enrolled1 locationNCT07289477
Recruiting
Phase 1
This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.
Parkinson Disease
iRegene Therapeutics Co., Ltd.5 enrolled1 locationNCT07102342
Recruiting
Phase 1
The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease
Early-onset Parkinson's Disease
iRegene Therapeutics Co., Ltd.6 enrolled1 locationNCT06608355
Recruiting
Phase 1Phase 2
The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease
Parkinson Disease
iRegene Therapeutics Co., Ltd.40 enrolled2 locationsNCT06167681